ბარიციტინიბისა და დექსამეტაზონის ეფექტურობა COVID-19-ით პაციენტებში

ანოტაცია

A novel coronaviral infection which was first discoveredin China in December 2019 rapidly spread around the worldand caused a pandemic. Reducing the lethality in hospital-ized patients is a major medical issue since the onset of pan-demic. Baricitinib is used in covid-19 patients with pneumo-nia at TSMU First University Clinic. From 70 patients 38(54.8%) were female and 32 (45.2) male. 62 (88.6%) patientswere from therapeutic unit and 8 (11.4%) patients from inten-sive care unit. Baricitinib was prescribed 4 mg oncedaily incombination with standard treatment. Patients in the thera-peutic unit were prescribed Baricitinib on the 6th-8th day afterthe onset of symptoms, and in patients in the intensive careunit on the 12th-16th day after the onset of symptoms. Barici-tinib was prescribed with hormonotherapy (Dexamethasone).From 8 (11.4%) intensive care unit patients who take Barici-tinib on the 12th-16th day after the onset of symptoms, 7 (10%)required invasive mechanical ventilation and 6 cases endedlethally. Thus, the maximum effectiveness of baricitinib isseen on the 5th-8th day after the onset of the clinical sings,while Baricitinib does not affect on the course and outcomeof disease when it prescribed in the later, oxygenation defi-ciency phase.